Suppr超能文献

血浆标志物可预测非痴呆患者的淀粉样蛋白、tau 蛋白、萎缩和认知变化。

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

机构信息

Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden.

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 141 83 Huddinge, Sweden.

出版信息

Brain. 2021 Oct 22;144(9):2826-2836. doi: 10.1093/brain/awab163.

Abstract

It is currently unclear whether plasma biomarkers can be used as independent prognostic tools to predict changes associated with early Alzheimer's disease. In this study, we sought to address this question by assessing whether plasma biomarkers can predict changes in amyloid load, tau accumulation, brain atrophy and cognition in non-demented individuals. To achieve this, plasma amyloid-β 42/40 (Aβ42/40), phosphorylated-tau181, phosphorylated-tau217 and neurofilament light were determined in 159 non-demented individuals, 123 patients with Alzheimer's disease dementia and 35 patients with a non-Alzheimer's dementia from the Swedish BioFINDER-2 study, who underwent longitudinal amyloid (18F-flutemetamol) and tau (18F-RO948) PET, structural MRI (T1-weighted) and cognitive testing. Our univariate linear mixed effect models showed there were several significant associations between the plasma biomarkers with imaging and cognitive measures. However, when all biomarkers were included in the same multivariate linear mixed effect models, we found that increased longitudinal amyloid-PET signals were independently predicted by low baseline plasma Aβ42/40 (P = 0.012), whereas increased tau-PET signals, brain atrophy and worse cognition were independently predicted by high plasma phosphorylated-tau217 (P < 0.004). These biomarkers performed equally well or better than the corresponding biomarkers measured in the CSF. In addition, they showed a similar performance to binary plasma biomarker values defined using the Youden index, which can be more easily implemented in the clinic. In addition, plasma Aβ42/40 and phosphorylated-tau217 did not predict longitudinal changes in patients with a non-Alzheimer's neurodegenerative disorder. In conclusion, our findings indicate that plasma Aβ42/40 and phosphorylated-tau217 could be useful in clinical practice, research and drug development as prognostic markers of future Alzheimer's disease pathology.

摘要

目前尚不清楚血浆生物标志物是否可用作独立的预后工具,以预测与早期阿尔茨海默病相关的变化。在这项研究中,我们通过评估血浆生物标志物是否可以预测无痴呆个体中淀粉样蛋白负荷、tau 积累、脑萎缩和认知的变化来解决这个问题。为此,我们在瑞典 BioFINDER-2 研究中,对 159 名无痴呆个体、123 名阿尔茨海默病痴呆患者和 35 名非阿尔茨海默病痴呆患者进行了血浆淀粉样蛋白-β42/40(Aβ42/40)、磷酸化 tau181、磷酸化 tau217 和神经丝轻链的测定,这些患者接受了纵向淀粉样蛋白(18F-flutemetamol)和 tau(18F-RO948)PET、结构 MRI(T1 加权)和认知测试。我们的单变量线性混合效应模型显示,血浆生物标志物与影像学和认知测量之间存在多种显著关联。然而,当所有生物标志物都包含在相同的多元线性混合效应模型中时,我们发现基线血浆 Aβ42/40 较低(P=0.012)可独立预测纵向淀粉样蛋白-PET 信号增加,而 tau-PET 信号增加、脑萎缩和认知能力下降则可独立预测高血浆磷酸化 tau217(P<0.004)。这些生物标志物的表现与 CSF 中测量的相应生物标志物一样好或更好。此外,它们的表现与使用 Youden 指数定义的二元血浆生物标志物值相似,这在临床上更容易实施。此外,血浆 Aβ42/40 和磷酸化 tau217 不能预测非阿尔茨海默病神经退行性疾病患者的纵向变化。总之,我们的研究结果表明,血浆 Aβ42/40 和磷酸化 tau217 可用作预测未来阿尔茨海默病病理的预后标志物,在临床实践、研究和药物开发中具有一定的应用价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/8557344/e099c8e0ecbb/awab163f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验